ERIBULIN
Background and Date of Approval
The FDA approved eribulin on November 15, 2010, for treatment of patients with metastatic breast cancer. On January 28, 2016, the FDA approved eribulin for treatment of unresectable and metastatic liposarcoma.
Uses
Eribulin was initially approved for metastatic (cancer that has spread to other parts of the body) or unresectable (cannot be removed with surgery) breast cancers not responding to anthracycline-based chemotherapy (a type of chemotherapy drug commonly used to treat various cancers). Recently, it gained FDA approval for liposarcoma treatment (a type of cancer originating from fat tissue), broadening its scope in addressing different types of cancer.
How is it administered?
Eribulin is administered solely by healthcare professionals through intravenous injections (injected directly into your veins), typically in a hospital or clinical setting. It is available in two strengths: 0.88mg and 0.5mg. Your doctor will determine the appropriate dosage for you based on factors such as your age and overall health condition.
Side Effects
Like all medications, Eribulin may cause side effects, though not everyone will experience them. Eribulin may lead to severe side effects, including sepsis (a severe infection), severe allergic reactions, and serious skin conditions such as Stevens-Johnson syndrome. Common side effects include decreased white or red blood cell counts, fatigue, nausea, vomiting, constipation, diarrhea, numbness or tingling sensations, fever, loss of appetite, weight loss, difficulty breathing, cough, joint, muscle, back pain, headache, and hair loss. If you experience any of these symptoms, you must inform your healthcare provider promptly.
Warnings
It is not recommended to take Eribulin if you are allergic to Eribulin or any of its other ingredients. Consult your doctor if you believe this applies to you. It is not recommended for children and adolescents younger than 18 years since the effects of Eribulin in this population are unknown. Before starting the treatment, you should inform your physician if you have fever, infections, liver, or heart problems. Before starting the treatment, give a detailed account of your medical history and medications.
Precautions
When using Eribulin, you need to avoid its use if you are pregnant, as it may cause harm to the fetus. Similarly, refrain from using it while breastfeeding due to uncertainty about its passage into breast milk. If you have lung disorders, inform your doctor before starting treatment, as Eribulin may worsen symptoms. Those with liver problems should consult their doctor before starting treatment, as Eribulin can affect liver function. Limit alcohol intake while using Eribulin to reduce the risk of liver damage, as it contains small amounts of alcohol. Additionally, be cautious of tiredness and dizziness caused by Eribulin, as it may impair your ability to drive or operate machinery.
Word of Advice
Your doctor will monitor your liver through blood tests and assess your heart function before and during treatment. If you are a woman of childbearing potential, use reliable contraception while taking Eribulin and for at least three months after stopping the medicine. Speak with your doctor about suitable contraception options to prevent pregnancy during treatment. Inform your oncologist if you require dental work, and always tell your dentist that you are undergoing cancer treatment. Eribulin can affect fertility in both men and women. If you have concerns about fertility, discuss this with your doctor before starting treatment. If you develop diarrhoea while taking Eribulin, aim to drink at least 2 litres of fluids daily and avoid alcohol, caffeine, milk products, and high-fat and high-fibre foods. If constipation occurs, increase your fluid intake, consume high-fibre foods, and undertake regular gentle exercise. Contact the hospital for advice; your doctor may prescribe laxatives to manage constipation. If you notice a loss of appetite, do not be concerned if it lasts for a day or two, but if it persists or you are losing weight, inform your nurse or dietitian. They may recommend nutritional supplements, dietary modifications, or adjustments to your eating patterns to address these issues.
References
Eisai Europe Limited, Electronic medicines compendium (EMC), [Revised on Jan 2023] [Accessed on Feb 2024], https://www.medicines.org.uk/emc/files/pil.4517.pdf Genentech, Inc, US Food and Drug Administration (FDA), [Revised on Jan 2016], [Accessed on Feb 2024], https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201532s015lbl.pdf Goodman & Gilman's Pharmacological Basis of Therapeutics, Pharmacotherapy of neoplastic drugs, 13th edition, 2018, 1187.
Frequently Asked Questions
What is the most important information I should know while taking Eribulin?
Eribulin can cause serious adverse effects such as low white blood cell count, numbness, tingling, and pain in the hands and feet. Inform your physician immediately if you face any of these symptoms.
Does Eribulin cause infertility?
Yes, Eribulin causes infertility in men and women. It is necessary to use effective birth control methods during the treatment and for three weeks (females) and 14 weeks (males) after the final dose of the injection.
Is hair loss caused by Eribulin reversible?
Hair loss is a common side effect of Eribulin Injection. It is reversible, but it depends totally on the severity of the hair loss and varies from person to person. Consult your doctor if you have severe hair loss.
Do I have to follow any special dietary requirements while taking Eribulin?
It depends upon the severity of the disease condition. You can have a normal diet until your physician tells you to follow any special food or diet chart. Check with your doctor if you have any nutrition concerns.
What should I do if I miss taking Eribulin?
It is important to get the injection at the right time. If you missed your appointment, contact your healthcare provider and schedule your dosing immediately. Keep follow-ups on your next schedule.